Mechanisms of resistance to anti-angiogenic treatments

Abstract

Hailed as the cancer treatment to end all the resistance to treatment, anti-angiogenic therapy turned out to be not quite what was promised. The hope that this therapeutic approach would not have suffered by the phenomenon of resistance was based on the fact that was targeting normal vessels rather than tumour cells prone to mutation and subject to drug induced selection. However, reality turned out to be more complex and since 1997, several mechanisms of resistance have been described to the point that the study of resistance to these drugs is now a very large field. Far from being exhaustive, this paper presents the main mechanisms discovered trough some examples.

Keywords

Angiogenic tumours / non-angiogenic tumours / anti-angiogenic treatment / resistance / hypoxia / vascular co-option

References

[1] Folkman J.Tumor angiogenesis: therapeutic implications..N Engl J Med1971;285:1182-6

[2] Kolata G.Hope in the lab: A special report; Tow drugs eradicate tumors in mice..The New York Times1998;

[3] Donnem T,Kuczynski EA,Vermeulen PB.Non-angiogenic tumours and their influence on cancer biology..Nat Rev Cancer2018;18:323-36

[4] Kuczynski EA,Pezzella F,Reynolds AR.Vessel co-option in cancer..Nat Rev Clin Oncol2019;Feb28[Epub ahead of print]

[5] Pezzella F,Tagliabue E,Sozzi G.Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis..Am J Pathol1997;151:1417-23 PMCID:PMC1858069

[6] Kerbel RS.Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents..Bioessays1991;13:31-6

[7] Weidner N,Pozza F,Allred EN.Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma..J Natl Cancer Inst1992;84:1875-87

[8] Weidner N,Welch WR.Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma..N Engl J Med1991;324:1-8

[9] Ferrara N.Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells..Biochem Biophys Res Commun1989;161:851-8

[10] Senger DR,Van de Water L,Dvorak HF.Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor..Cancer Res1990;50:1774-8

[11] Mise M,Higashituji H,Niwano M.Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor..Hepatology1996;23:455-64

[12] Obermair A,Mayerhofer K,Seifert M.Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival..Int J Cancer1997;74:455-8

[13] Takahashi Y,Bucana CD,Ellis LM.Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer..Cancer Res1995;55:3964-8

[14] Toi M,Hoshina S,Kondo S.Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer..Clin Cancer Res1995;1:961-4

[15] O’Reilly MS,Shing Y,Rosenthal RA.Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma..Cell1994;79:315-28

[16] O’Reilly MS,Chen C.Angiostatin induces and sustains dormancy of human primary tumors in mice..Nat Med1996;2:689-92

[17] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[18] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[19] Ameratunga M,Wheeler H,Simes J.Anti-angiogenic therapy for high-grade glioma..Cochrane Database Syst Rev.2018;Nov2211:CD008218

[20] Verhoeff JJ,Claes A,van Linde ME.Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme..BMC Cancer2009;9:444 PMCID:PMC2801683

[21] Mackey JR,Gelmon KA,Chia SK.Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials..Cancer Treat Rev2012;38:673-88

[22] Lopez A,Vasilakopoulou M,Ajani JA.Targeting Angiogenesis in Colorectal Carcinoma..Drugs2019;79:63-74

[23] Kerr RS,Segelov E,Falcon B.Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial..Lancet Oncol2016;17:1543-57

[24] Stratigos M,Voutsina A,V. G.Targeting angiogenesis in small cell lung cancer..Transl Lung Cancer Res2016;5:389-400 PMCID:PMC5009078

[25] Manzo A,Carillio G,Sandomenico C.Angiogenesis Inhibitors in NSCLC..Int J Mol Sci2017;18:20121 PMCID:PMC5666703

[26] Vasudev NS.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions..Angiogenesis2014;17:471-94 PMCID:PMC4061466

[27] Bergers G.Modes of resistance to anti-angiogenic therapy..Nat Rev Cancer2008;8:592-603 PMCID:PMC2874834

[28] Pezzella F,Andreola S,Pastorino U.Angiogenesis in primary lung cancer and lung secondaries..Eur J Cancer1996;32A:2494-500

[29] Breast Cancer Progression Working PartyEvidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party..Lancet2000;355:1787-8

[30] Bridgeman VL,Foo S,Daley F.Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models..J Pathol2017;241:362-74 PMCID:PMC5248628

[31] Stessels F,Van der Auwera I,Van den Heuvel E.Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia..Br J Cancer2004;90:1429-36 PMCID:PMC2409675

[32] Frentzas S,Bridgeman VL,Foo S.Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases..Nat Med2016;22:1294-302 PMCID:PMC5104270

[33] Jeong HS,Liao S,Cui CH.Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases..J Natl Cancer Inst2015;107:djv155 PMCID:PMC4651102

[34] Colpaert CG,Van Beest P,Goovaerts G.Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition..Histopathology2003;42:530-40

[35] Valiente M,Jin X,Zhang XH.Serpins promote cancer cell survival and vascular co-option in brain metastasis..Cell2014;156:1002-16 PMCID:PMC3988473

[36] Carbonell WS,Sibson N.The vascular basement membrane as “soil” in brain metastasis..PLoS One2009;4:e5857 PMCID:PMC2689678

[37] Bugyik E,Reiniger L,Tóvári J.Lack of angiogenesis in experimental brain metastases..J Neuropathol Exp Neurol2011;70:979-91

[38] de Groot JF,Kumar AJ,Eterovic K.Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice..Neuro Oncol2010;12:233-42 PMCID:PMC2940588

[39] di Tomaso E,Kamoun WS,Auluck PK.Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape..Cancer Res2011;71:19-28 PMCID:PMC3074948

[40] Norden AD,Wen PY.Antiangiogenic therapies for high-grade glioma..Nat Rev Neurol2009;5:610-20

[41] Nürnberg A,Grosse R.Nucleating actin for invasion..Nat Rev Cancer2011;11:177-87

[42] Kuczynski EA,Bar-Zion A,Butz H.Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma..J Natl Cancer Inst2016;108: PMCID:PMC5017954

[43] Folkman J.What is the evidence that tumors are angiogenesis dependent?.J Natl Cancer Inst1990;82:4-6

[44] Seaman S,Saha S,Yang MY.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature..Cancer cell2017;31:501-15 PMCID:PMC5458750

[45] Ribatti D.Tumor refractoriness to anti-VEGF therapy..Oncotarget2016;7:46668-77 PMCID:PMC5216828

[46] Graeber TG,Jacks T,Koch CJ.Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours..Nature1996;379:88-91

[47] Yu JL,Coomber BL,Kerbel RS.Effect of p53 status on tumor response to antiangiogenic therapy..Science2002;295:1526-8

[48] Pàez-Ribes M,Hudock J,Okuyama H.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis..Cancer Cell2009;15:220-31 PMCID:PMC2874829

[49] Ribatti D.Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway..Cancer Treat Rev2011;37:344-52

[50] Depner C,Böğürcü N,Aburto MR.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance..Nat Commun2016;7:12329 PMCID:PMC4974575

[51] Nakajima EC.Metabolic symbiosis in cancer: refocusing the Warburg lens..Mol Carcinog2013;52:329-37

[52] Pisarsky L,Fagiani E,Goosen RW.Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy..Cell Rep2016;15:1161-74 PMCID:PMC4870473

[53] Poon E,Ashcroft M.Targeting the hypoxia-inducible factor (HIF) pathway in cancer..Expert Rev Mol Med2009;11:e26

[54] Bensaad K.Hypoxia and metabolism in cancer..Adv Exp Med Biol2014;772:1-39

[55] Ward C,Mullen P,Harrison DJ.New strategies for targeting the hypoxic tumour microenvironment in breast cancer..Cancer Treat Rev2013;39:171-9

[56] Rey S,Koritzinsky M.Molecular targeting of hypoxia in radiotherapy..Adv Drug Deliv Rev2017;109:45-62

[57] Suh YE,Henley-Smith R,Leek R.Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma..Br J Cancer2017;116:1057-64 PMCID:PMC5396120

[58] Li J,Li X,Li Y.Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy..Bioorg Med Chem2019;27:1145-58

[59] Adams RH.Molecular regulation of angiogenesis and lymphangiogenesis..Nat Rev Mol Cell Biol2007;8:464-78

[60] Gacche RN.Redundant angiogenic signaling and tumor drug resistance..Drug Resist Updat2018;52:1350-62

[61] Nissen LJ,Hedlund EM,Zhao X.Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis..J Clin Invest2007;117:2766-77 PMCID:PMC1994630

[62] Akl MR,Ayoub NM,Prabhu SA.Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies..Oncotarget2016;7:44735-62 PMCID:PMC5190132

[63] Alessi P,Camozzi M,Albini A.Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist..Eur Cytokine Netw2009;20:225-34

[64] Ma H,Xu H,Xin M.The Inhibitory Effect of Propylene Glycol Alginate Sodium Sulfate on Fibroblast Growth Factor 2-Mediated Angiogenesis and Invasion in Murine Melanoma B16-F10 Cells In Vitro..Mar Drugs2019;17: PMCID:PMC6562581

[65] Papadopoulos N.The PDGF/PDGFR pathway as a drug target..Mol Aspects Med2018;62:75-88

[66] Heldin CH.Targeting the PDGF signaling pathway in tumor treatment..Cell Commun Signal2013;11:97 PMCID:PMC3878225

[67] Meng MB,Deng L,Chao J.Pericytes: a double-edged sword in cancer therapy..Future Oncol2015;11:169-79

[68] Chen Z,Hu J.Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy..Neoplasma2016;63:173-82

[69] Aird WC.Phenotypic heterogeneity of the endothelium: II. Representative vascular beds..Circ Res2007;100:174-90

[70] Aird WC.Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms..Circ Res2007;100:158-73

[71] Hida K,Akiyama K,Hida Y.Heterogeneity of tumor endothelial cells..Cancer Sci2013;99:1391-5

[72] Bussolati B,Deregibus MC.The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway..J Mol Med (Berl)2006;84:852-63

[73] Hida K MN,Hida Y.Heterogeneity of tumor endothelial cells and drug delivery..Adv Drug Deliv Rev2016;99:140-7

[74] Guerrouahen BS,Kaoud NA,Beauchamp MC.Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer..Mol Cancer Ther2014;13:3123-36

[75] Mitsuhashi A,Saijo A,Aono Y.Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab..Nat Commun2015;6:8792 PMCID:PMC4686833

[76] Ma S,Hu W,Coleman R.The role of tumor microenvironment in resistance to anti-angiogenic therapy..F1000Res2018;7:326 PMCID:PMC5854986

[77] Pasqualini R,Kain R,Sakamoto M.Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis..Cancer Res2000;60:722-7 PMCID:PMC4469333

[78] Pastorino F,Marimpietri D,Gambini C.Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy..Cancer Res2003;63:7400-9

[79] Hinnen P.Vascular disrupting agents in clinical development..Br J Cancer2007;96:1159-65 PMCID:PMC2360146

[80] Lorusso PM,Hunsberger S.Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?.J Clin Oncol2011;29:2952-5

[81] KEGG PATHWAY. (Accessed March April 2019, 2019, at https://www.kegg.jp/kegg/pathway.html.)